Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial
Titel:
Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial
Auteur:
Walter, Thomas Lievre, Astrid Coriat, Romain Malka, David Elhajbi, Farid Di Fiore, Fréderic Hentic, Olivia Smith, Denis Hautefeuille, Vincent Roquin, Guillaume Perrier, Marine Dahan, Laetitia Granger, Victoire Sobhani, Iradj Mineur, Laurent Niccoli, Patricia Assenat, Eric Scoazec, Jean-Yves Le Malicot, Karine Lepage, Côme Lombard-Bohas, Catherine